Clinical Trials Logo

Clinical Trial Summary

Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03089658
Study type Expanded Access
Source Merck KGaA, Darmstadt, Germany
Contact
Status Approved for marketing
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT04261855 - Targeted Therapy and Avelumab in Merkel Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03816332 - Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Phase 1
Recruiting NCT05947500 - Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03304639 - Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Phase 2
Active, not recruiting NCT03599713 - A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) Phase 2
Recruiting NCT05896839 - Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Phase 1/Phase 2